SCY-078

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidiasis, Invasive

Conditions

Candidiasis, Invasive, Candidemia

Trial Timeline

Nov 15, 2017 → May 24, 2023

About SCY-078

SCY-078 is a phase 3 stage product being developed by Scynexis for Candidiasis, Invasive. The current trial status is completed. This product is registered under clinical trial identifier NCT03363841. Target conditions include Candidiasis, Invasive, Candidemia.

What happened to similar drugs?

5 of 20 similar drugs in Candidiasis, Invasive were approved

Approved (5) Terminated (4) Active (12)

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03363841Phase 3Completed

Competing Products

20 competing products in Candidiasis, Invasive

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPhase 1
29
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Fluconazole + MicafunginAstellas PharmaApproved
35
Micafungin + CaspofunginAstellas PharmaPhase 3
40
Micafungin + FluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPhase 2
35
micafungin + caspofunginAstellas PharmaPhase 3
40
micafungin + amphotericin B deoxycholateAstellas PharmaPhase 3
32
FK463Astellas PharmaPhase 2
35
Micafungin + Liposomal Amphotericin BAstellas PharmaPhase 3
40
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
36
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
36
L-743,872MerckPre-clinical
26
CaspofunginMerckPhase 2
35
L-743,872MerckPhase 2
27
Caspofungin + Amphotericin B DeoxycholateMerckPhase 2
27
Caspofungin acetate + PlaceboMerckPhase 2
27
Caspofungin + Normal SalineMerckApproved
43